Consensus Jade Biosciences, Inc.

Stocks

JBIO

US0080642061

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 23:00:00 16/07/2026 +03			5-day change	1st Jan Change
20.48 ^USD	-6.31%		-9.10%	+32.73%

07-02	Jade Biosciences to Receive up to $22 Million as Part of Licensing Deal With Paragon Therapeutics	MT
06-29	Jade Biosciences, Inc.(NasdaqCM:JBIO) added to Russell Microcap Growth Benchmark Index	CI

Evolution of the Average Target: Jade Biosciences, Inc.

Evolution of the Target Price: Jade Biosciences, Inc.

Changes in Analyst Recommendations: Jade Biosciences, Inc.

1ce56eb6650d4085087e20c89.OK-5FKtL021NlwrTWjlPERfIXWzh-nMrk-ViASPlydE.UPrYYd8nty4ewjqQNg84RSWBPFTUzDBt9LRXMnqKv6Fv1uZOxim6Jj3eYQ~9a13714caced3035fe28d770fef813fe

Analysts' recommendations: Jade Biosciences, Inc.

06-15	UBS Initiates Jade Biosciences at Buy With $45 Price Target	MT
06-01	Wedbush Raises Price Target on Jade Biosciences to $45 From $34, Maintains Outperform Rating	MT
05-08	Wedbush Raises Price Target on Jade Biosciences to $34 From $24, Keeps Outperform Rating	MT
05-08	Wedbush Raises Price Target on Jade Biosciences to $34 From $24, Maintains Outperform Rating	MT
03-09	William Blair Initiates Coverage on Jade Biosciences With Outperform Rating	MT
01-07	HC Wainwright Initiates Jade Biosciences at Buy With $25 Price Target	MT
12-23	Wedbush Adjusts Price Target on Jade Biosciences to $24 From $19, Maintains Outperform Rating	MT
11-14	Wedbush Adjusts Price Target on Jade Biosciences to $19 From $18, Maintains Outperform Rating	MT
09/10/25	BTIG Initiates Jade Biosciences at Buy With $28 Price Target	MT
14/08/25	Wedbush Adjusts Price Target on Jade Biosciences to $18 From $17, Maintains Outperform Rating	MT
16/06/25	Guggenheim Upgrades Jade Biosciences to Buy From Neutral, Price Target is $14	MT
05/05/25	Stifel Nicolaus Initiates Coverage on Jade Biosciences With Buy Rating, $19 Price Target	MT
02/05/25	TD Cowen Initiates Coverage on Jade Biosciences With Buy Rating	MT
18/06/24	Guggenheim Downgrades Aerovate Therapeutics to Neutral From Buy	MT
18/06/24	TD Cowen Downgrades Aerovate Therapeutics to Hold From Buy	MT
18/06/24	Evercore ISI Downgrades Aerovate Therapeutics to In Line From Outperform, Adjusts Price Target to $2 From $27	MT
17/06/24	Top Midday Decliners	MT
17/06/24	Jefferies Downgrades Aerovate Therapeutics to Hold From Buy, Cuts Price Target to $2 From $65; Shares Plummet	MT
17/06/24	Wells Fargo Downgrades Aerovate Therapeutics to Equalweight From Overweight, Cuts Price Target to $2 From $35; Shares Plummet	MT
17/06/24	BTIG Downgrades Aerovate Therapeutics to Neutral From Buy	MT
17/06/24	Wedbush Downgrades Aerovate Therapeutics to Neutral From Outperform, Adjusts Price Target to $3 From $41	MT
15/08/23	Wedbush Adjusts Aerovate Therapeutics Price Target to $48 From $50, Maintains Outperform Rating	MT
17/05/23	Wedbush Lowers Aerovate Therapeutics' Price Target to $50 From $54, Keeps Outperform Rating	MT
01/03/23	Guggenheim Initiates Aerovate Therapeutics at Buy With $36 Price Target	MT
12/12/22	Wedbush Raises Aerovate Therapeutics' PT to $54 From $27 on Increased Confidence in Inhaled TKIs, AV-10; Keeps Outperform Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	JADE BIOSCIENCES, INC.					+121.87%
	LONZA GROUP AG					+15.1%
	REVOLUTION MEDICINES, INC.					+8.58%
	IQVIA HOLDINGS INC.					+12.18%
	BEONE MEDICINES AG					+33.27%
	CELLTRION, INC.					+46.08%
	ASCENDIS PHARMA A/S					+12.21%
	MEDPACE HOLDINGS, INC.					-10.75%
	EUROFINS SCIENTIFIC SE					+2.49%
	ICON PUBLIC LIMITED COMPANY					+5.66%
	Average					+24.67%
	Weighted average by Cap.					+17.18%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

21.86USD

Average target price

48.50USD

Spread / Average Target

+121.87%

High Price Target

74.00USD

Spread / Highest target

+238.52%

Low Price Target

40.00USD

Spread / Lowest Target

+82.98%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

UBS
Wedbush
Edgewater Research
William Blair & Co.
HC Wainwright
BTIG
Guggenheim
Stifel Nicolaus
TD Cowen
Evercore ISI
Jefferies & Co.
Wells Fargo Securities
Cowen